Evaluation of (68)Gallium- DOTATATE PET/CT for Detecting Primary and Metastatic Neuroendocrine Tumors

Trial Profile

Evaluation of (68)Gallium- DOTATATE PET/CT for Detecting Primary and Metastatic Neuroendocrine Tumors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Gallium 68-DOTATATE (Primary)
  • Indications Neuroendocrine tumours
  • Focus Diagnostic use
  • Most Recent Events

    • 13 Jan 2017 Planned End Date changed from 1 Sep 2021 to 1 Dec 2022.
    • 22 Nov 2016 New trial record
    • 02 Nov 2016 Results (n=31) of a retrospective analysis assessing 68Ga-DOTATATE PET/CT Scan for localizing insulinoma, published in the Journal of Clinical Endocrinology and Metabolism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top